OSE Immunotherapeutics SA, a clinical-stage biotechnology company headquartered in Nantes, France, continues to make significant strides in the health care sector, particularly within the biotechnology industry. As a company listed on the NYSE Euronext Paris, OSE Immunotherapeutics has been at the forefront of developing innovative immunotherapies targeting immune-oncology and immune-inflammation. With a market capitalization of €112,694,080 and a recent close price of €5.02 as of December 4, 2025, the company has demonstrated resilience despite a challenging financial landscape, as indicated by its price-to-earnings ratio of -3.17.
The company’s portfolio is robust, featuring several promising products in various stages of clinical trials. Among these, Tedopi stands out as it progresses through Phase III clinical trials for the treatment of non-small cell lung cancer. Additionally, Tedopi is being evaluated in Phase II trials for pancreatic and ovarian cancers, showcasing its potential versatility in oncology applications. OSE-279, another key product, is currently in a Phase I/II clinical trial targeting patients with advanced solid tumors or lymphomas, further emphasizing the company’s commitment to addressing complex cancer types.
OSE-127, a humanized monoclonal antibody, is in Phase II trials for ulcerative colitis and Sjögren’s Syndrome, highlighting OSE Immunotherapeutics’ expansion into immune-inflammatory diseases. The company is also exploring new frontiers with FR104, which is in Phase I trials for rheumatoid arthritis treatment. Additionally, BI 765063 is undergoing Phase I trials for solid tumors, while OSE-230, an agonist antibody against ChemR23, aims to resolve chronic inflammation. The company’s innovative approach is further exemplified by its work on CLEC-1, a therapeutic target in immune-oncology, and BiCKI, a novel bispecific checkpoint inhibitor platform targeting PD-1 to combat cancer resistance mechanisms.
OSE Immunotherapeutics has established a strong network of collaborations and partnerships, enhancing its research and development capabilities. Notable collaborations include partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital. Additionally, strategic alliances with industry leaders such as Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation underscore the company’s commitment to advancing its therapeutic pipeline.
Founded in 2012 and formerly known as OSE Pharma SA, the company rebranded to OSE Immunotherapeutics SA in May 2016, reflecting its focused mission in immunotherapy. As it continues to navigate the competitive biotechnology landscape, OSE Immunotherapeutics remains dedicated to developing groundbreaking therapies that address unmet medical needs in oncology and immune-inflammatory diseases. With its strategic partnerships and innovative pipeline, the company is well-positioned to make significant contributions to the health care sector in the coming years.
